Cancer Immunol Res

Enzalutamide, an Androgen Receptor Antagonist, Enhances Myeloid Cell-Mediated Immune Suppression and Tumor Progression.

Consiglio CR, Udartseva O, Ramsey KD, Bush C, Gollnick SO

Cancer Immunol Res 8 (9) 1215-1227 [2020-09-00; online 2020-07-13]

Camila Consiglio DDLS Fellow

Abstract B110: Proinflammatory allogeneic dendritic cells promote activation of bystander immune cells and indirectly license antigen-specific T-cells

Fotaki G, Jin C, Kerzeli IK, ..., Yu D, Essand M

Cancer Immunol Res 7 (2_Supplement) B110-B110 [2019-02-01; online 2019-02-01]

Abstract A128: Tumor endothelial cells say IDO to CD40-stimulating immunotherapy

Dimberg A, Karampatzakis A, Tuit S, ..., Essand M, Georganaki M

Cancer Immunol Res 7 (2_Supplement) A128-A128 [2019-02-01; online 2019-02-01]

Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.

Oei VYS, Siernicka M, Graczyk-Jarzynka A, ..., Kyte JA, Malmberg KJ

Cancer Immunol Res 6 (4) 467-480 [2018-04-00; online 2018-02-19]

Affiliated researcher

Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production.

Pico de Coaña Y, Poschke I, Gentilcore G, ..., Masucci GV, Kiessling R

Cancer Immunol Res 1 (3) 158-162 [2013-09-00; online 2013-08-02]

SciLifeLab Fellow Yumeng Mao